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Nuclear factor erythroid 2-related factor 2 (Nrf2) provides a 
cellular defense against oxidative stress by inducing the 
expression of antioxidant and detoxification enzymes. The 
calcium antagonist, verapamil, is an FDA-approved drug 
prescribed for the treatment of hypertension. Here, we show 
that verapamil acts as a potent Nrf2 activator without causing 
cytotoxicity, through degradation of Kelch-like ECH-associated 
protein 1 (Keap1), a Nrf2 repressor. Furthermore, verapamil- 
induced Keap1 degradation is prominently mediated by a 
p62-dependent autophagic pathway. Correspondingly, verapamil 
protects cells from acetaminophen-induced oxidative damage 
through Nrf2 activation. These results demonstrated the 
underlying mechanisms for the protective role of verapamil 
against acetaminophen-induced cytotoxicity. [BMB Reports 
2017; 50(2): 91-96]
INTRODUCTION
The nuclear factor erythroid 2-related factor 2 (Nrf2)-Kelch-like 
ECH-associated protein 1 (Keap1) pathway protects cells 
against oxidative stress-mediated damage through the increase 
of antioxidant and detoxification enzymes (1-3). Keap1, a 
negative regulator of Nrf2, steadily leads to proteasomal 
degradation of Nrf2 in unstressed cells (1, 2, 4, 5). Recently, 
Nrf2 activators have been developed as promising therapeutic 
drugs for various diseases such as liver disease (6, 7), neuro-
degenerative disease (8), and chronic renal disease (9). 
Verapamil has been reported to inhibit calcium uptake in 
vitro and in vivo (10) and is used as a Food and Drug 
Administration (FDA)-approved drug for the treatment of 
hypertension (11). Notably, recent studies have reported that 
verapamil induces autophagy in colon adenocarcinoma (12) 
and attenuates the accumulation of p62/sqstm1 (hereafter 
referred to as p62) and ubiquitinated proteins through an 
increase in the autophagic flux (13, 14). 
Acetaminophen (APAP) is widely used as an analgesic and 
antipyretic drug. However, an overdose of APAP induces 
hepatotoxicity in humans and rodents (15, 16). Notably, APAP- 
induced hepatotoxicity is associated with oxidative stress 
induced by N-Acetyl-p-benzoquinone imine (NAPQI), a 
reactive metabolite of APAP (17). 
In this study, we demonstrate that verapamil acts as a potent 
Nrf2 activator and protects cells from APAP-induced cell 
death. In addition, we elucidate the underlying mechanisms 
for verapamil-mediated Nrf2 activation. 
RESULTS
Verapamil activates Nrf2 without causing cytotoxicity
Nrf2 is known to function as an important transcription factor 
that translocates to the nucleus and induces the transcription 
of genes for antioxidant or detoxification proteins (3, 18). As 
our previous research suggested that autophagic Keap1 
degradation might represent a possible mechanism of Nrf2 
activation, we speculated that the pro-autophagic effects of 
verapamil might, therefore, influence Nrf2 function. To verify 
nuclear translocation of Nrf2, HEK293T cells were transfected 
with HA-tagged Nrf2 (H-Nrf2) and HA-tagged Keap1 
(H-Keap1) with concomitant treatment of 100 M verapamil 
for 18 h. Immunofluorescence analysis revealed that verapamil 
increased the amount of Nrf2 in the nucleus (Fig. 1A). To 
further examine whether verapamil mediated the accumula-
tion of nuclear Nrf2, mouse hepatoma (Hepa1c1c7) cells and 
MEF cells (data not shown) were treated with 100 M 
verapamil for 18 h and the nuclear fractions were isolated. 
Immunoblot analysis showed that the nuclear amounts of Nrf2 
were increased (Fig. 1B). Consistent with this result, we 
Verapamil mediates p62-dependent Nrf2 activation
Da Hyun Lee, et al.
92 BMB Reports http://bmbreports.org
Fig. 1. Verapamil activates Nrf2 without causing cytotoxicity. (A) 
HEK 293T cells treated with DMSO or verapamil (100 M) for 
18 h. HEK 293T cells expressing HA-Nrf2 were subjected to 
immunofluorescence analysis using an anti-HA antibody. Cell 
nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). 
Scale bars, 10 m. (B) Nuclear fractions of Hepa1c1c7 cells 
treated with verapamil (100 M) for 18 h were subjected to 
immunoblot analysis with antibodies against Nrf2 and Lamin B. 
(C) Hepa1c1c7 cells transfected with vectors for H-Nrf2, H-Keap1, 
as well as with the luciferase reporter plasmid pNqo1-ARE and 
pRL-TK (internal control) were treated with verapamil for 18 h. 
The transfected cells were lysed and we determined the luciferase 
activity. (D) Total RNA isolated from Hepa1c1c7 cells treated as 
described in (B) was subjected to quantitative qRT-PCR analysis 
for the mRNAs of GSTA1, HO-1, and Nqo-1. (E) Cell viability 
was estimated using a Cell titer-Glo assay kit. The live cell 
number was expressed as the absorbance at luminescence in 
Hepa1c1c7 cells. (F) Hepa1c1c7 cells treated with or without 
NAC (1 mM) prior to verapamil (100 M) treatment were 
subjected to qRT-PCR analysis for mRNAs of GSTA-1, HO-1, and 
Nqo-1. Data are presented as the means ± SD from three 
independent experiments. *P ＜ 0.05; N.S.: not significant. 
Fig. 2. Verapamil mediates Keap1 degradation via an autophagic 
pathway. (A) Hepa1c1c7 cells were treated with verapamil (100 
M) for the indicated times. Lysates of Hepa1c1c7 cells were 
subjected to immunoblot analysis with antibodies against Keap1, 
LC3-II, and -actin (loading control). (B) Densitometric analysis of 
Keap1 immunoblots was obtained in (A). Total RNA isolated from 
cells treated as described was subjected to qRT-PCR analysis for 
the mRNA of Keap1 (C). (D) Densitometric analysis of LC3-II/- 
actin immunoblots was obtained in (A). (E) ATG5＋/＋ or ATG5−/−
MEF cells were incubated in the absence or presence of 
verapamil (100 M) for 18 h. Lysates of ATG5＋/＋ or ATG5−/−
MEF cells were subjected to immunoblot analysis with antibodies 
against Keap1, LC3-II, and -actin (loading control). (F) Densito-
metric analysis of Keap1 immunoblots was obtained in (E). Total 
RNA isolated from cells treated as described in (E) was subjected 
to qRT-PCR analysis for mRNAs of Keap1 (G) and ATG5 (H). (I) 
ATG7＋/＋ or ATG7−/− MEF cells were incubated in the absence 
or presence of verapamil (100 M) for 18 h. Lysates of ATG7＋/＋
or ATG7−/− MEF cells were subjected to immunoblot analysis 
with antibodies against Keap1, LC3-II, and -actin (loading 
control). (J) Densitometric analysis of Keap1 immunoblots was 
obtained in (H). Total RNA isolated from cells treated as 
described in (I) was subjected to qRT-PCR analysis for mRNAs of 
Keap1 (K) and ATG7 (L). Data are the mean ± SD from three 
independent experiments. *P ＜ 0.05.
demonstrated verapamil-mediated up-regulation of the 
transactivation activity of Nrf2 using a luciferase reporter assay 
(Fig. 1C). This verapamil-induced increase in Nrf2 activity was 
accompanied by an upregulation of Nrf2 target genes 
including GSTA1, HO-1, and Nqo-1 in Hepa1c1c7 (Fig. 1D) 
and MEF (Supplementary Fig. 1) cells. 
To examine whether verapamil treatment resulted in 
cytotoxicity, verapamil-treated cells were subjected to cell 
viability analysis. We found that verapamil did not cause 
cytotoxicity in Hepa1c1c7 (Fig. 1E) or MEF cells (Supplementary 
Fig. 1). Next, as reactive oxygen species (ROS) can activate 
Nrf2 by oxidative modification of Keap1, a negative regulator 
of Nrf2 (19), we examined whether verapamil-induced 
upregulation of Nrf2 target genes was caused by ROS- 
mediated Nrf2 activation. Hepa1c1c7 cells were co-treated 
with verapamil (100 M) and N-acetyl-L-cysteine (NAC), as a 
known ROS scavenger. However, the results showed that NAC 
did not affect the verapamil-mediated upregulation of Nrf2 
target genes (Fig. 1F). Taken together, these findings indicate 
that verapamil acts as a potent Nrf2 activator in an ROS- 
independent manner.
Verapamil mediates Keap1 degradation via an autophagic 
pathway
To identify whether verapamil activation of the Nrf2-Keap1 
pathway is related to the known autophagic Keap1 degradation 
mechanism (1, 3, 5, 19), Hepa1c1c7 cells were treated with 
verapamil (100 M) for the indicated times. Keap1 protein and 
mRNA levels were determined by immunoblotting and 
quantitative qRT-PCR assays, respectively. Verapamil reduced 
the abundance of Keap1 protein in a time-dependent manner, 
whereas the amount of Keap1 mRNA remained unaffected 
(Fig. 2A-C). We also found that verapamil increased the 
amount of LC3-II, an autophagy marker protein, in Hepa1c1c7 
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Fig. 3. p62 is required for verapamil-induced Keap1 degradation 
and Nrf2 activation. (A) p62＋/＋ or p62−/− MEF cells were 
incubated in the absence or presence of verapamil (100 M) for 
18 h. Lysates of p62＋/＋ or p62−/− MEF cells were subjected to 
immunoblot analysis with antibodies against Keap1, p62, and 
-actin (loading control). (B) Densitometric analysis of Keap1 
immunoblots was obtained in (A). Total RNA isolated from cells 
treated as described in (A) was subjected to qRT-PCR analysis for 
mRNAs of Keap1 (C), GSTA1 (D), HO-1 (E), and Nqo-1 (F). (G) 
Hepa1c1c7 cells transfected with control siRNA (si-control) or p62 
siRNA were treated with DMSO or verapamil (100 M) for 18 h. 
The cells were lysed and subjected to immunoblot analysis with 
antibodies against Keap1, p62, and -actin (loading control). (H) 
Densitometric analysis of Keap1 immunoblots was obtained in 
(G). qRT-PCR analysis of mRNAs of Keap1 (I), GSTA1 (J), HO-1 
(K), and Nqo-1 (L). Data are presented as the means ± SD from 
three independent experiments. *P ＜ 0.05.
Fig. 4. Verapamil alleviates APAP-induced cytotoxicity via Nrf2 
activation. (A) Hepa1c1c7 cells were pretreated with APAP (10 
mM) for 1 h and incubated in the absence or presence of 
verapamil (100 M) for 18 h. Cell viability was estimated using a 
Cell titer-Glo assay kit. The live cell number was expressed as 
the absorbance at luminescence. (B) TUNEL analysis of Hepa1c1c7
cells treated as in (A) and quantitation of TUNEL analysis. (C) 
Hepa1c1c7 cells treated as described in (A) were lysed and 
subjected to immunoblot analysis with antibodies against cleaved 
PARP, cleaved caspase-3, Keap1, and -actin (loading control). (D) 
Apoptosis in Hepa1c1c7 cells pretreated with APAP and in-
cubated in the absence or presence of verapamil were detected 
by FACS analysis for Annexin V and PI staining. (E) Early 
apoptosis. (F) Late apoptosis. (G) ROS levels were determined 
using CM-H2DCFH-DA. Representative images are shown. Quanti-
tative analysis of cells treated as described in (A). The relative 
dichlorofluorescein fluorescence was calculated by averaging the 
levels of fluorescence from 80-100 cells after subtracting the 
background fluorescence obtained using a fluorescence microscope.
Total RNA isolated from cells treated as described in (A) was 
subjected to qRT-PCR analysis for mRNAs of GSTA1 (H) and 
Nqo-1 (I). Data are presented as the means ± SD from three 
independent experiments. *P ＜ 0.05.
(Fig. 2D) and MEF cells (Supplementary Fig. 2). As shown in 
Fig. 1, we observed that the verapamil-induced degradation of 
Keap1 was accompanied by an upregulation of the mRNA 
levels of Nrf2 target genes, including GSTA1, HO-1, and 
Nqo-1 in Hepa1c1c7 (Supplementary Fig. 3) and MEF cells 
(Supplementary Fig. 2).
Based on these results, we examined whether the verapamil- 
induced Keap1 degradation was mediated by an autophagic 
process. To do this, we first examined the autophagic activity 
of verapamil with the use of an autophagic flux assay 
(Supplementary Fig. 4). We treated wild-type ATG5 (ATG5＋/＋) 
and autophagy-defective ATG5 (ATG5−/−) MEF cells with 
verapamil (100 M). The results showed that verapamil- 
induced Keap1 degradation was markedly inhibited in 
ATG5−/− MEF cells compared to that in ATG5＋/＋ MEF cells, 
whereas the levels of Keap1 mRNA were not altered in either 
cell type (Fig. 2E-H). Similar experiments with another autophagy- 
defective ATG7 (ATG7−/−) MEF cell line confirmed that 
verapamil (100 M) did not affect Keap1 degradation (Fig. 2I-L). 
Accordingly, these results indicated that verapamil-mediated 
Keap1 degradation is mediated by an autophagic process.
p62 is required for verapamil-induced Keap1 degradation and 
Nrf2 activation
The autophagy adaptor protein, p62, has recently been 
identified as being essential for Nrf2 activation (2, 5, 20). To 
examine whether verapamil-induced Nrf2 activation is 
dependent on p62, wild-type (p62＋/＋) and p62-deficient 
(p62−/−) MEF cells were treated with verapamil (100 M). 
Immunoblot analysis indicated that verapamil-induced Keap1 
degradation was markedly blocked in p62−/− MEF cells 
compared to p62＋/＋ MEF cells (Fig. 3A, B). However, the 
levels of Keap1 mRNAs were not changed in p62 MEF cells 
(Fig. 3C). Correspondingly, we showed that a p62-deficiency 
downregulated verapamil-mediated induction of Nrf2 target 
genes including GSTA1, HO-1, and Nqo-1 (Fig. 3D-F). In line 
with these observations, small interfering RNA (siRNA)- 
mediated knockdown of p62 showed effects similar to those of 
verapamil on Keap1 degradation associated with Nrf2 target 
gene upregulation in Hepa1c1c7 cells (Fig. 3G-L). It is 
Verapamil mediates p62-dependent Nrf2 activation
Da Hyun Lee, et al.
94 BMB Reports http://bmbreports.org
reported that p62 phosphorylation (p-S351) activates the Nrf2 
pathway (21). We also found that verapamil is significantly 
induced by phosphorylation of p62 at Ser351 (Supplementary 
Fig. 5). Together, our observations suggest that verapamil- 
induced Nrf2 activation is mediated by a p62-dependent 
autophagic pathway. 
Verapamil protects cells from APAP-induced cytotoxicity via 
Nrf2 activation
It is well known that an overdose of APAP leads to 
ROS-mediated cell death (22, 23). Notably, Nrf2 has been 
reported as an important transcription factor for protecting 
cells from APAP-mediated cell death (24, 25). To explore the 
antioxidant function of verapamil as a potent Nrf2 activator in 
the pathological setting, we examined the effects of verapamil 
on APAP-mediated cell death. First, we tested whether 
verapamil protects against APAP-induced apoptotic cell death 
using a cell viability assay, flow cytometric analysis, and 
TUNEL analyses. The results showed that verapamil inhibited 
APAP-induced cell death (Fig. 4A and Fig. 4D-F) and decreased 
TUNEL- positive cells (Fig. 4B). Consistent with these results, 
the expression levels of cleaved poly(ADP)ribose polymerase 
(PARP) and cleaved caspase-3 proteins were partially inhibited 
in response to verapamil (Fig. 4C). To determine whether this 
antioxidant role is caused by Keap1 degradation-induced Nrf2 
activation in this context, we examined the expression levels 
of Keap1 protein and Nrf2 target genes. The combination of 
verapamil and APAP showed additive effects on the induction 
of Nrf2 target genes (Fig. 4H-I and Supplementary Fig. 6) 
associated with the degradation of Keap1 (Fig. 4C). These 
results suggest that verapamil prevents APAP-induced 
apoptotic cell death by Nrf2 activation through Keap1 
degradation. Given that APAP leads to intracellular ROS 
accumulation and elicits cell death, we next examined the 
effect of verapamil on APAP-induced ROS accumulation in 
Hepa1c1c7 cells. We found that verapamil significantly 
blocked APAP-induced ROS accumulation (Fig. 4G). 
DISCUSSION
A Nrf2-Keap1 pathway is an essential tool for protecting cells 
against oxidative stress. The underlying molecular mechanism 
of Nrf2 activation can be explained by a “hinge and latch 
model” in which the Kelch-repeat domain of the Keap1 
homodimer interacts with one entity of Nrf2 via a low-affinity 
DLG motif (latch) or a high-affinity ETGE motif (hinge) in the 
Neh2 domain of Nrf2 (2, 26). In response to oxidative stress, 
Keap1 is modified at one or more of its cysteine residues, 
which induces a conformational change that interrupts its 
binding to the low-affinity DLG motif of Nrf2. The unbound 
Nrf2 is then translocated to the nucleus and induces the 
transcription of its target genes, including GSTA1, HO-1, and 
Nqo-1 (2). 
Numerous natural or synthetic compounds have been 
shown to activate Nrf2 and protect cells from oxidative 
damage in human and rodent tissuse. Most of these 
electrophilic compounds modify cysteine residues of Keap1, 
leading to Nrf2 activation (7). One such compound is oltipraz, 
a synthetic Nrf2 activator that is currently undergoing clinical 
trials and appears to represent a potential therapeutic drug for 
diverse diseases, including nonalcoholic steatohepatitis, 
multiple sclerosis, muscular dystrophy, and skin cancer (27). 
However, this electrophilic Nrf2 activator also modifies 
cysteine residues of other proteins and may therefore exhibit 
potentially unwanted effects some Nrf2 activator (7). 
To address this concern, it is necessary to develop 
non-electrophilic drugs for specific Nrf2 activators. Recently, 
the autophagy adaptor protein, p62, has been identified as a 
crucial protein in the activation of the Nrf2-Keap1 pathway (5, 
20, 28). The p62 protein specifically interacts with Keap1 and 
competitively inhibits the interaction between Nrf2 and Keap1 
(20, 29). This disruption leads to the stabilization of Nrf2 with 
concomitant increased in the expression of Nrf2 antioxidant 
target genes. Furthermore, phosphorylation of Ser351 on p62 
mediated by the mammalian target of rapamycin complex 1 
(mTORC1) or other kinases strongly facilitates the interaction 
with Keap1 and activates Nrf2 (21).
Recently, in a search for non-electrophilic Nrf2 activators we 
identified that ezetimibe, an FDA-approved drug for the 
treatment of hyperlipidemia, also acts as a potent Nrf2 
activator without causing cytotoxicity. The underlying 
mechanism of ezetimibe on Nrf2 activation was found to be 
mediated through AMP-activated protein kinase (AMPK)- 
dependent phosphorylation of the Ser351 site on p62 (30). We 
also previously identified that Sestrin2, a stress-responsive 
protein, activates Nrf2 by promoting p62-dependent autophagic 
Keap1 degradation through its interaction with the p62- 
Keap1-Nrf2 complex (5). Together, these findings indicate that 
p62-dependent autophagic Keap1 degradation in addition to 
Nrf2 stabilization represent likely mechanisms of Nrf2 activation.
Accordingly, in the current study, we found that verapamil, 
an FDA-approved drug for the treatment of hypertension, also 
activates Nrf2 by promoting p62-dependent autophagic Keap1 
degradation. Verapamil is known to be a L-type calcium 
channel blocker and inhibits cytosolic Ca2＋ levels (31). Vera-
pamil is widely used in the treatment of cardiac vascular diseases 
such as cardiac arrhythmias, hypertension, and angina pectoris 
(32). Verapamil has also been reported to induce the autophagic 
pathway; for example, in colon cancer, verapamil treatment 
induces massive autophagy-like processes and leads to necrotic 
cell death (12). Furthermore, verapamil was shown to suppress 
saturated fatty acid-induced protein inclusion (p62 and ubiqui-
tinated protein) by restoring the autophagic flux (13). Consistent 
with these reports, we found that verapamil-induced Keap1 
degradation is mediated by an autophagic pathway. 
We also found that verapamil has a protective role against 
APAP overdose-induced cell death, an effect also previously 
demonstrated to be associated with Nrf2 activation. APAP is 
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commonly used as an analgesic and antipyretic drug (33); 
however, it induces hepatotoxicity when taken in overdose 
(15). APAP is metabolized by cytochrome P450 (CYP2E1) to 
generate NAPQI, which in turn may interrupt the repression of 
Nrf2 by modifying the cysteine residues of Keap1. In addition, 
NAPQI induces the depletion of glutathione, resulting in ROS 
accumulation. Furthermore, APAP significantly induces the accu-
mulation of mitochondrial ROS by inhibiting the mitochondrial 
respiratory chain (16, 34). Notably, several groups have re-
ported that Nrf2 has a protective role against hepatotoxicity 
produced by APAP in vivo and in vitro (24, 25, 35). 
Accordingly, our current finding that verapamil mediated 
Nrf2 activation by promoting p62-dependent autophagic 
degradation of Keap1 and attenuated ROS accumulation, 
provides a suitable explanation for its protective role in APAP- 
induced cell death. Therefore, we propose that verapamil 
represents a promising FDA-approved drug for the treatment of 
oxidative stress-mediated damage through its action as a 
potent Nrf2 activator. Further studies are needed to investigate 
verapamil’s effect on the Nrf2 activation using in vivo 
hepatotoxicity model.
MATERIALS AND METHODS
See supplementary information for Materials and Methods.
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